WO2014115169A3 - Dispersion solide de crizotinib - Google Patents
Dispersion solide de crizotinib Download PDFInfo
- Publication number
- WO2014115169A3 WO2014115169A3 PCT/IN2014/000052 IN2014000052W WO2014115169A3 WO 2014115169 A3 WO2014115169 A3 WO 2014115169A3 IN 2014000052 W IN2014000052 W IN 2014000052W WO 2014115169 A3 WO2014115169 A3 WO 2014115169A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crizotinib
- present
- solid dispersion
- preparation
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
La présente invention concerne un composé de sel d'oxalate de crizotinib, son procédé de préparation et des compositions pharmaceutiques le comprenant. La présente invention concerne également un nouveau procédé pour la préparation de crizotinib à l'aide d'un nouvel intermédiaire. La présente invention concerne en outre un procédé pour la purification de crizotinib. La présente invention concerne en outre une nouvelle dispersion solide amorphe de crizotinib en combinaison avec un support pharmaceutiquement acceptable, son procédé de préparation et des compositions pharmaceutiques la comprenant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN329CH2013 | 2013-01-24 | ||
IN329/CHE/2013 | 2013-01-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014115169A2 WO2014115169A2 (fr) | 2014-07-31 |
WO2014115169A3 true WO2014115169A3 (fr) | 2016-02-25 |
Family
ID=51228161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2014/000052 WO2014115169A2 (fr) | 2013-01-24 | 2014-01-23 | Dispersion solide de crizotinib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014115169A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115919866A (zh) * | 2022-12-07 | 2023-04-07 | 深圳海王医药科技研究院有限公司 | 特泊替尼固体分散体及其制备方法 |
CN115887406B (zh) * | 2022-12-24 | 2024-02-13 | 山东理工职业学院 | 一种克唑替尼胶囊的制备方法 |
CN116688139B (zh) * | 2023-06-25 | 2024-03-29 | 深圳市新阳唯康科技有限公司 | 一种克唑替尼药物组合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080300273A1 (en) * | 2005-12-05 | 2008-12-04 | Pfizer Inc. | Method of Treating Abnormal Cell Growth |
US7858643B2 (en) * | 2004-08-26 | 2010-12-28 | Agouron Pharmaceuticals, Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
US8217057B2 (en) * | 2005-12-05 | 2012-07-10 | Pfizer Inc. | Polymorphs of a c-MET/HGFR inhibitor |
-
2014
- 2014-01-23 WO PCT/IN2014/000052 patent/WO2014115169A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858643B2 (en) * | 2004-08-26 | 2010-12-28 | Agouron Pharmaceuticals, Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
US20080300273A1 (en) * | 2005-12-05 | 2008-12-04 | Pfizer Inc. | Method of Treating Abnormal Cell Growth |
US8217057B2 (en) * | 2005-12-05 | 2012-07-10 | Pfizer Inc. | Polymorphs of a c-MET/HGFR inhibitor |
Non-Patent Citations (1)
Title |
---|
KONING ET AL.: "Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066", ORG. PROCESS RES. DEV., vol. 15, no. 5, 2011, pages 1018 - 1026, XP055078841, DOI: doi:10.1021/op200131n * |
Also Published As
Publication number | Publication date |
---|---|
WO2014115169A2 (fr) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
CA2894892A1 (fr) | Derives d'acide boronique et leurs utilisations therapeutiques | |
EP3040072A4 (fr) | Composition pharmaceutique ayant un composé pyrimidine comme principe actif | |
WO2015081257A3 (fr) | Dérivés d'aminopyridine utilisés comme inhibiteurs de kinases de la famille tam | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
CA2830549C (fr) | Procedes et compositions pour la preparation de noribogaine a partir de voacangine | |
WO2015104658A3 (fr) | Dispersion solide amorphe de dapagliflozine et procédé pour la préparation de dapagliflozine amorphe | |
HK1220965A1 (zh) | 鹽、相關的晶體形式、其製備方法以及含有其的藥物組合物 | |
WO2014153495A9 (fr) | Nouveaux inhibiteurs de stats3 | |
WO2014076712A3 (fr) | Dispersion solide de chlorhydrate de lurasidone | |
EP3421038A4 (fr) | Composé de naphtyridine, composition pharmaceutique et leur utilisation | |
WO2015092810A3 (fr) | Forme amorphe d'idélalisib | |
MX2016001138A (es) | Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo. | |
WO2015002755A3 (fr) | Composés pour le traitement du paludisme | |
EP2871187A4 (fr) | Nouveau composé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique le contenant à titre de principe actif | |
WO2014115169A3 (fr) | Dispersion solide de crizotinib | |
WO2014009970A3 (fr) | Dispersion solide de linagliptine | |
WO2014197536A3 (fr) | Nouvelles bêta lactames en tant que modulateurs d'absorption du glutamate et leurs procédés d'utilisation | |
WO2014105777A8 (fr) | Sel de dichlohydrate de cobicistat | |
IN2012CH01309A (fr) | ||
WO2016020408A3 (fr) | Composés pour prévenir l'ototoxicité | |
WO2014195977A3 (fr) | Nouveaux polymorphes de vismodegib | |
WO2015044434A3 (fr) | Fluoro-9-méthyl-β-carboline | |
WO2015087343A3 (fr) | Procédé amélioré pour la préparation de nilotinib et de sels pharmaceutiquement acceptables de celui-ci | |
AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14743833 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14743833 Country of ref document: EP Kind code of ref document: A2 |